T he combination of two cytotoxic drugs, a platinum and nonplatinum agent, is the standard of care for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) and good performance status (PS, 0 to 1). 1 In an attempt to improve activity and efficacy of current regimens, a pharmacogenetic approach has been advocated. Pharmacogenetics may reduce the variation in how individual patients respond to medicines by tailoring therapies to their genetic profile. 2 Cisplatin activity is mediated through the formation of cisplatin-DNA adducts. Removal of these adducts, which leads to chemoresistance, is mainly carried out by the nucleotide excision repair system, which consists of at least 30 identified genes, including excision repair crosscomplementing group 1 (ERCC1) and xeroderma pigmentosum group D (XPD). 3 Single-nucleotide polymorphisms (SNP) in any of these genes may modulate repair capacity and contribute to individual variations in chemotherapy response. In vitro analysis showed that the C/T SNP at codon 118 of the ERCC1 gene affected mRNA and protein levels, leading to differential cisplatin sensitivity. 4 Furthermore, clinical data suggested a possible correlation of this SNP with clinical outcome and tumor response to platinum-based chemotherapy in advanced colorectal cancer and a significant correlation with survival in advanced NSCLC. [5] [6] [7] [8] Two nonsynonymous polymorphisms occurring in XPD, the aspartic acid 312 asparagine (Asp 312 Asn) and the lysine 751 glutamine (Lys 751 Gln) have been associated with a differential DNA repair efficiency. 9, 10 Some studies in lung cancer patients showed no significant association between clinical outcome and the C/C genotype in codon 118 of ERCC1 11, 12 and with polymorphisms at codons 312 and 751 in XPD. 7, 8, 12, 13 Other gene, the x-ray repair cross-complementing group 3 (XRCC3), belongs to the homologous recombination pathway, which actively repairs the DNA double-strand breaks induced by chemotherapy. The polymorphism in codon 241 (Thr to Met) of XRCC3 has been associated with the level of bulky DNA adducts in leukocytes of healthy subjects, 14 with chemosensitivity to therapy 15 and with a higher risk of developing lung cancer. 16 Moreover, TP53 plays a central role in DNA synthesis, repair, and apoptosis; a polymorphism at codon 72 (Arg to Pro) 17 has been associated with survival in head and neck cancer patients receiving cisplatin-based chemoradiotherapy, with patients harboring the Arg allele having longer survival than those with the Pro allele. 18 Human NSCLC cell lines with TP53 mutations at codons 273 and 282 were resistant to cisplatin/gemcitabine in the presence of the 72 Arg allele but not in that of the 72 Pro allele. 19 Ribonucleotide reductase, a key enzyme for DNA synthesis, is involved in DNA repair and in gemcitabine metabolism. A C to A substitution in the 59 noncoding region of the subunit M1 (RRM1), located 37 base-pairs upstream of the start codon and has been linked to RRM1 expression levels, with high levels in patients with the variant allele. 20 The metabolic inactivation of gemcitabine is catalyzed primarily by cytidine deaminase (CDA), but few studies have evaluated the pharmacogenetics of this enzyme reporting controversial results. In particular, Gilbert et al 21 have observed a significant decrease in deamination activity of gemcitabine in a CDA variant characterized by the nonsynonymous polymorphism of lysine 27 glutamine (Lys 27 Gln), resulting from an A to C substitution in exon 79, whereas Kirch et al 22 reported opposite results with cytarabine as the substrate. Moreover, sensitivity to cytarabine was not changed by introducing polymorphic 27Gln CDA into yeast CDA-null mutants. 23 Other in vitro studies did not show any relationship between CDA activity and sensitivity to gemcitabine or cytarabine 24, 25 ; only cells with transfected CDA and thus with a very high CDA activity were less sensitive to gemcitabine. 26 Hence, CDA might be a key enzyme in the mechanism of inactivation of gemcitabine, but the role of its polymorphism is still controversial. Nevertheless, few clinical studies have shown a positive association between CDA SNP and drug toxicity. 27, 28 Taken together, these observations suggest that several SNPs may affect key genes involved in cisplatin and gemcitabine mechanism of action and may influence clinical outcome. Therefore, we retrospectively evaluated the correlations of ERCC1 C118T; P53 Arg72Pro; XRCC3 Thr241Met; XPD Lys751Gln; RRM1 C524T; CDA Lys27Gln; and CDA C435T polymorphisms on germ line DNA obtained from NSCLC patients receiving cisplatin/gemcitabine-based therapy with drug response, toxicity, and survival.
PATIENTS AND METHODS

Patient Selection Criteria
Chemotherapy-naive patients with histologically or cytologically proven NSCLC and measurable clinical stage IIIB or stage IV disease were eligible if they also met the following criteria: an Eastern Cooperative Oncology Group performance status Յ2, age Ͼ18 years, life expectancy Ͼ3 months, adequate bone marrow reserve (leukocyte count Ͼ4.0 ϫ 10 9 /L and platelet count Ն100 ϫ 10 9 /L), adequate liver (bilirubin level Յ1.5 mg/dL and alanine aminotransferase/ aspartate aminotransferase Ͻ3 times the upper limit of normal), and renal function (creatinine level Յ1.5 mg/dL). The main exclusion criteria were active infections, concomitant malignancy, or a second primary malignancy, recent myocardial infarction, unstable angina, symptomatic brain metastases, or hypercalcemia. The primary endpoints were response to chemotherapy and toxicities according to SNPs genotyping status and secondary endpoints were progressionfree survival (PFS) and overall survival (OS).
Eligible types of treatment were as follows: cisplatin/ gemcitabine regimens (75 mg/m 2 of cisplatin infused over 60 minutes given on day 1 plus 1 g/m 2 of gemcitabine administered intravenously over 30 minutes on day 1 and day 8 and every 3 weeks), cisplatin/taxol regimens (75 mg/m 2 of cisplatin on day 1 and 175 mg/m 2 of taxol on day 1 and every 3 weeks), cisplatin/vinorelbine regimens (75 mg/m 2 of cisplatin on day 1, plus 25 mg/m 2 of vinorelbine on day 1 and day 8 and every 3 weeks), or gemcitabine alone. All chemotherapeutic drugs were administered intravenously, and patients were treated for four to six cycles, with a median of four cycles. No patient had received thoracic radiotherapy. Treatment was discontinued in case of disease progression, major toxicities, or according to the patient's or physician's decision. Assessment of tumor response was carried out by computed tomography scan every three cycles. Responses were assessed using Response Evaluation Criteria in Solid Tumors. 29 The best overall response for each patient was reported, and all responses were reviewed by an independent radiologist and had to be confirmed 28 days or more after the initial documentation of response. Toxicity was expressed as the number of patients who experienced a certain grade of an adverse event at least once during the study. Hematologic and nonhematologic toxicities were recorded at day 1 and 8 of every treatment course. The worst toxicity grade for each patient in all chemotherapy cycles was reported. Toxicities were assessed using National Cancer Institute common terminology criteria (version 3.0). The analysis of the samples was done in a blinded fashion relative to the clinical outcome. The study was approved by an Ethical Review Committee at the hospital and all patients gave their signed informed consent to SNPs genotyping analyses.
DNA Extraction and SNP Genotyping
Genomic DNA was extracted from whole blood samples (5 ml) using the QIAamp DNA extraction kit on Biorobot EZ1 instrument (Qiagen, Milan, Italy) according to the manufacturer's instructions. In this exploratory investigation, we evaluated seven SNPs of the ERCC1, P53, XRCC3, XPD, RRM1, CDA genes according to the following criteria: (a) the minor allele frequency of the SNP is Ͼ10% among Caucasian; (b) coding SNPs including nonsynonymous and synonymous SNP; and (c) SNPs that have been associated with cancer risk or clinical outcome in previous investigations. The genes, nucleotide substitutions, and reference SNP identification numbers of the seven SNPs evaluated in this study are summarized in Table 1 .
SNPs were studied with Taqman probe-based assays using primers and probe sequence as previously published by other authors. 12, 30 The polymerase chain reactions (PCRs) were done using 20 ng of genomic DNA diluted in 11.875 L DNase-RNase-free water, 12.5 L of TaqMan Universal PCR Master Mix with AmpliTaq Gold, and 0.625 L of the assay mix (forward and reverse specific primers and the specific probes), in a total volume of 25 L. Amplification was done under the following conditions:50°C for 2 minutes, 95°C for 10 minutes followed by 40 cycles of 92°C for 15 seconds, and 60°C for 1 minute. Fluorescence in each sample well was measured before and after PCR using ABI Prism 7300 Sequence Detection System. Data were analyzed using the Allelic Discrimination Program (Applied Biosystems, Foster City, CA). For each polymorphism, a minimum of 20 randomly selected DNA samples were genotyped at least twice to confirm the results.
Statistical Analysis
All patients meeting the criteria for eligibility were considered for analysis. Association between genotypes and response was evaluated using a logistic regression model. The results, expressed as odds ratios with 95% confidence intervals (95% CIs), are reported. The same approach was used to investigate the association between genotypes and toxicity. PFS was defined as the time from the onset of treatment to the first appearance of progressive disease or death for any cause; patients known to be alive and free of progressive disease at the time of analysis were censored at their last available follow-up assessment. OS was defined as the time from the beginning of treatment to the date of death from any cause or the date of the last follow-up. Survival curves were estimated using the Kaplan-Meier method. The Cox proportional hazards model was used for univariate analysis that tests demographic characteristics (gender, age, and smoking status) and clinical features (performance status, histology, and stage) for their association with PFS and OS. Variables with a p value Ͻ0.1 in the univariate model were considered for the multivariate analysis. The results are expressed as hazard ratios (HRs) with 95%CIs. Statistical significance was set at p Ͻ 0.05. Analysis was performed using SAS (Statistical Analysis System; SAS Institute Inc., Cary, NC, version 9.1) software.
RESULTS
Patient Characteristics
From June 2001 to August 2008, a total of 192 Caucasian patients were enrolled in this study. Patient characteristics are shown in Table 2 . Median age was 63 years (range, 25-81 years); 74.0% were male; 74.5% were smokers; 94.3% had performance status 0 -1; 41.7% had adenocarcinoma, and 76.0% had stage IV disease. Of the 192 patients studied, 165 patients (85.9%) received cisplatin/gemcitabine regimens, 15 (7.8%) cisplatin/taxol regimens, 9 (4.7%) cisplatin/vinorelbine regimens, and 3 (1.6%) received gemcitabine alone.
Genotype Information
The polymorphisms of genes ERCC1 C118T, P53 Arg72Pro, XRCC3 Thr241Met, and XPD Lys751Gln were evaluated in 189 patients who were treated with cisplatinbased regimens, whereas the polymorphisms of genes RRM1 C524T, CDA C435T, CDA Lys27Gln were analyzed in 168 patients who were treated with gemcitabine-based regimens. The distribution of all these polymorphisms and the allelic frequencies are shown in Table 3 . All polymorphisms followed Hardy-Weinberg's equilibrium and genotype frequencies for all polymorphisms were comparable with those reported in previous studies in a Caucasian population of NSCLC patients. 12,30 XRCC3 Thr241Met was found more frequently in smoker patients (p ϭ 0.006) and RRM1 CT genotype in stage IV (p ϭ 0.03).
No significant correlations were detected among ERCC1 C118T, P53 Arg72Pro, XRCC3 Thr241Met, XPD Lys751Gln, CDA Lys27Gln, CDA C435T genotypes and age, gender, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), histology, or clinical stage.
Correlation Between Polymorphisms and Response to Chemotherapy
The overall best response rate was 32.3%, stable disease 25.0%, and disease progression 42.7%. A significant correlation was shown between better response to cisplatin/ gemcitabine-based chemotherapy and CDA C435T genotype: 54.6% of the patients carrying the CDA T/T genotype experienced partial response, whereas only 28.8% of CDA C/T and 27.5% of CDA C/C patients responded to therapy (p ϭ 0.03; Table 4 ). In the multivariate logistic regression model including performance status, age, and type of treatment regimen, the CDA 435 T/T genotype remained significantly associated with a better response to cisplatin/gemcitabinebased chemotherapy (p ϭ 0.04, Table 4 ). No significant correlations were observed between ERCC1 C118T, P53 Arg72Pro, XRCC3 Thr241Met, XPD Lys751Gln, CDA Lys27Gln, and RRM1 C524T genotypes and objective response.
Toxicity Analysis
As outlined in Table 5 , a significant difference in severe nonhematologic toxicity was observed according to CDA C435T genotype, with grade Ն3 in 14.3% of heterozygous patients for the CDA C/T, in contrast to 2.8% of those who were C/C homozygous (p ϭ 0.03). No other significant differences in toxicity were found with respect to the other polymorphisms. In the multivariate logistic regression model including performance status, age, and type of treatment regimen, the CDA 435 C/T genotype was associated with a significantly increased risk of nonhematologic toxicity of grade Ն3 (p ϭ 0.02, Table 5 ).
Survival Analysis
At a median follow-up of 24.6 months (25th-75th percentile, 14.5-40.8 months), 66.7% (128/192) of patients died. The median OS and PFS time were 12.7 and 4.7 months, respectively. At univariate analysis, age Ͼ63 years (median value) and ECOG-PS 0 were statistically significantly associated with longer PFS (p ϭ 0.022 and p ϭ 0.002, respectively, Table 6 ). The univariate analysis of OS showed that age Ͼ63 years (HR ϭ (Table 6 ). No significant differences in PFS and OS were observed with respect to ERCC1 C118T, P53 Arg72Pro, XRCC3 Thr241Met, CDA Lys27Gln, CDA C435T, and RRM1 C524T genotypes. A multivariate Cox regression model for PFS showed that the XPD 751 CC genotype (HR ϭ 0.58; 95% CI ϭ 0.39 -0.85; p ϭ 0.006, Figure 1 ), ECOG-PS 0 (HR ϭ 0.58; 95% CI ϭ 0.42-0.79; p ϭ 0.0006), and age Ͼ63 years (HR ϭ 0.61; 95% CI ϭ 0.45-0.84; p ϭ 0.002) were significantly associated with longer PFS. A multivariate Cox regression model for OS showed that age Ͼ63 years (HR ϭ 0.59; 95% CI ϭ 0.41-0.86; p ϭ 0.007), ECOG-PS 0 (HR ϭ 0.49; 95% CI ϭ 0.33-0.73; p ϭ 0.0005), never-smoker (HR ϭ 0.45; 95% CI ϭ 0.24 -0.85; p ϭ 0.014), and adenocarcinoma histology (HR ϭ 0.57; 95% CI ϭ 0.38 -0.86; p ϭ 0.008) were the independent prognostic factors for OS (Table 6 ).
DISCUSSION
In this study, we evaluated polymorphisms of key genes involved in the mechanism of action or metabolism of cisplatin and gemcitabine. CDA, an enzyme involved in the pyrimidines salvage pathway, is the major gemcitabine inactivation enzyme. Therefore, patients with impaired CDA activity might develop strong toxicities after administration of gemcitabine, while CDA overexpression in tumor tissues might reduce the antitumor efficacy of this drug. An in vitro study has demonstrated resistance to gemcitabine in cells overexpressing CDA. 31 Three main SNPs were identified in the CDA gene: CDA 435 CϾT not encoded for an amino acid change, CDA 79 AϾC encoded for a lysine to glutamine amino acid change (K27Q), and CDA 208GϾA encoded for an alanine to threonine amino acid change (A70T). 23 In Asians, the 208 GϾA polymorphism is associated with alteration of gemcitabine pharmacokinetics and subsequent severe hematologic toxicities. 27, 28 Another pivotal clinical study, in Caucasians, has demonstrated that the 79 AϾC polymorphism could have an impact on CDA activity and clinical outcome in patients treated with gemcitabine plus cisplatin, thus suggesting that screening for this mutation could be a predictive marker at the bedside. 30 In this study, we evaluated two SNPs, the CDA 435 CϾT and CDA 79 AϾC (Lys27Gln) identified in the CDA gene; the genotype frequencies for these polymorphisms were comparable with those reported in previous studies in a Caucasian population of NSCLC patients. 21 Nevertheless, the CDA G208A was not detected in Caucasians 32 and for this reason, it is not evaluated in our study. Our data show that the CDA C435T variant T allele was associated with a better response, suggesting reduced enzyme activity conferred by this allele resulted in a higher level of drug availability. Based on the results of the analyses of the 345 CϾT SNP, we observed that decreased CDA activity might have been responsible for the severe drug toxicity found in this data setting. A significant difference in severe nonhematologic toxicity was observed according to CDA genotype, with grades 3-4 in 14.3% of heterozygous patients for the CDA 345 CT, in contrast to 2.8% of those who were CC homozygous (p ϭ 0.03), and this effect was also maintained in the multivariate model (p ϭ 0.02) after adjusting for performance status, age, and type of treatment regimen. Our result was specific to gastrointestinal toxicity. Esophagitis reflects a direct damage on the mucosal tissues of the gastrointestinal tract. Chemotherapy-induced nausea/vomiting is thought to be mediated by a complex interplay between the gastrointestinal tract and the central and peripheral nervous systems.
Although the exact mechanism has yet to be determined, tissue damage to the normal gastrointestinal tissue is thought to be a contributing factor. No other significant differences in toxicity were found with respect to the other polymorphisms. Nevertheless, CDA C435T polymorphism was not associated with survival. The multivariate analysis of PFS showed that the polymorphism of XPD 751 C/C variant, which is essential for transcription during nucleotide excision repair, was associated with longer PFS. Matullo et al 14 found that a polymorphism in codon 751 (Lys to Gln) of XPD was associated with differences in the levels of bulky DNA adducts. Among XPD 751 GlnGln carriers, extremely low levels of DNA adducts were detected in smokers, whereas nonsmokers had high levels. Experimental evidence indicates that XPD overexpression leads to cisplatin resistance. 33 In contrast, it has also been reported that XPD variant alleles (Gln751 or Asn312) were associated with reduced DNA repair capacity as measured by host cell reactivation assay. 34 Nevertheless, gene-smoking interaction for these XPD polymorphisms has been documented; Gln751 and Asn312 variants were risk factors of lung cancer in nonsmokers but protective factors in heavy smokers, when compared with the Lys751 and Asp312 homozygous wild types. 35 In our study, the patients with XPD 751 C/C variant were heavy smokers conferring a better clinical outcome. The exact mechanism of how cigarette smoking changes the DNA repair capacity (DRC) posed by each genotype of these DNA repair genetic polymorphisms is unknown. One possible explanation may be that different DRCs of different genotypes are overwhelmed by heavy smoking exposure. Alternately, cigarette smoking may stimulate DRC in response to the DNA damage caused by tobacco carcinogens, because heavy smokers among both lung cancer patients and controls may have more proficient DRC in lymphocytes than non-or light smokers, and DNA repair gene expression was increased in heavy smokers. 35 No other polymorphism in any of the genes included in this study was significantly related to survival, and these data are in agreement with those of a recent study carried out by De las Peñas et al 12 in advanced NSCLC patients treated with cisplatin plus gemcitabine. Interestingly, in this study, patients harboring XRCC3 Met241Met genotype lived longer than patients with other XRCC3 241 polymorphisms, even if no correlation with response has been reported. Previous studies on ERCC1 and XPD SNPs and their predictive role of clinical outcome reported controversial results; furthermore, most of these trials were carried out in patients treated with different platinum-based regimens, 7, 8, 11, 36, 37 not allowing definitive conclusions. Multiple reasons may explain the different results obtained in the association between some SNPs and survival. Most published studies are in different tumor types, with a variety of treatment regimens and population differences. In our study, focusing only on scientifically sensitive comparisons, a policy of not making adjustments for multiple comparisons is taken to avoid missing important findings. Nevertheless, this study has a number of limitations.
First, the effects of the SNP on the enzymatic or nonenzymatic functions of the CDA 435CϾT protein is not exactly known. Second, these findings should be validated in a prospective study with a larger group of patients and a more comprehensive series of polymorphisms. Third, it is quite unlikely that the effect of a single common sequence variant on outcomes will be easily detectable in a population-based study such as the present one, whereas a combination of multiple sequence variants functioning in the same biochemical pathway might be more important in the identification of different risks for survival and other clinically relevant efficacy outcomes. Fourth, the retrospective nature of this study and the possibility for ascertainment bias, particularly with regard to toxicity outcomes. Although multiple sources of documentation were searched to find as much toxicity information as possible, documentation of toxicity is at the discretion of the treating clinicians, and this can vary by physician, by type of regimen being used, and by treatment on or off protocol. Grading of toxicity can also be subjective, although the widespread acceptance and use of the National Cancer Institute Common Toxicity Criteria within the medical oncology group has in large part standardized toxicity grading among clinicians. Of note, although there may have been variable recording and grading of toxicity outcomes, it is very unlikely that there would have been a systematic difference based on polymorphism status, which was unknown to the physicians at the time of treatment. Nevertheless, prospective studies will be needed to eliminate many of these potential biases and to validate the hypotheses generated from this study. Furthermore, our analysis includes a highly homogeneous cohort of advanced NSCLC patients who may have contributed to highlight the relevance of these variants in the response, toxicity, and PFS of patients treated with cisplatin/ gemcitabine-based regimen.
In conclusion, to our knowledge, this is the first in vivo study to analyze the predictive role of CDA 435CϾT polymorphism. We reported a correlation of this polymorphism with response and toxicity in NSCLC patients treated with cisplatin/gemcitabine-based therapy. We believe that the analysis of CDA genotype should be incorporated into future prospective trials with gemcitabine, alone or in combination, to identify the best marker to secure the administration of this widely prescribed anticancer therapy.
